secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2025-12-17T23:59:59+00:00
Accession:  0001493152-25-028075
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari raises ~$5M in equity; exchanges $4M notes for warrants
-------------------------------------------------------------

- Gross proceeds ~$5M from 10,043,774 ADSs at $0.3883/unit plus pre-funded warrants to insiders for $1M+.
- Non-cash reduction of ~$4M in 2026 Notes via exchange for pre-funded warrants and Note Exchange Warrants.
- Warrants exercisable after shareholder approval; Series G exercise price $0.3883, 5-year term.
- Ladenburg Thalmann acts as placement agent; 8.0% fee, 0.5% mgmt fee, and 504,300 placement agent warrants.
- Net proceeds for R&D and working capital; offering closed Dec. 17, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000149315225028075/0001493152-25-028075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000149315225028075/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-028075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer